Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04345718 · ClinicalTrials.gov registry record · Phase 2
EXHIT ENTRE Comparative Effectiveness Trial
A Phase 2 study, sponsored by Gavin Bart.
- Completed
- Registry status
- Phase 2
- Development phase
- 344
- Enrollment target
NCT04345718 is a Phase 2 study that has completed, run by Gavin Bart. The registered enrollment target is 344 participants.
The verdict
NCT04345718, a Phase 2 study, has completed, sponsored by Gavin Bart.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 344 participants
- Enrollment target
Study Summary
This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction consultation service (ACS) and agreeing to initiate a medication for OUD (MOUD). Participants will be randomly assigned to XR-BUP or TAU to be received within 72 hours of anticipated hospital discharge. Follow up will occur at approximately 34, 90, and 180 days following hospital discharge.
Interventions
- DRUG Extended Release Buprenorphine
- DRUG Treatment as Usual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04345718
The ClinicalTrials.gov registry entry for NCT04345718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gavin Bart, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extended Release Buprenorphine is the first listed.
NCT04345718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04345718 about?
NCT04345718 is a clinical study titled "EXHIT ENTRE Comparative Effectiveness Trial". This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction consultation service ...
What is the current status of trial NCT04345718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 344 participants. The study started on 2021-08-09. Estimated completion is 2025-08-27.
What interventions are being tested in trial NCT04345718?
The interventions under investigation include: Extended Release Buprenorphine (DRUG), Treatment as Usual (DRUG).
Who is sponsoring clinical trial NCT04345718?
This trial is sponsored by Gavin Bart, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.